Tryptamine Attenuates Experimental Multiple Sclerosis Through Activation of Aryl Hydrocarbon Receptor

Tryptamine is a naturally occurring monoamine alkaloid which has been shown to act as an aryl hydrocarbon receptor (AHR) agonist. It is produced in large quantities from the catabolism of the essential amino acid tryptophan by commensal microorganisms within the gastrointestinal (GI) tract of homeot...

Full description

Saved in:
Bibliographic Details
Main Authors: Nicholas Dopkins (Author), William Becker (Author), Kathryn Miranda (Author), Mike Walla (Author), Prakash Nagarkatti (Author), Mitzi Nagarkatti (Author)
Format: Book
Published: Frontiers Media S.A., 2021-01-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_8d1e3529ef0d439ea862c9f5fb1ad7ad
042 |a dc 
100 1 0 |a Nicholas Dopkins  |e author 
700 1 0 |a William Becker  |e author 
700 1 0 |a Kathryn Miranda  |e author 
700 1 0 |a Mike Walla  |e author 
700 1 0 |a Prakash Nagarkatti  |e author 
700 1 0 |a Mitzi Nagarkatti  |e author 
245 0 0 |a Tryptamine Attenuates Experimental Multiple Sclerosis Through Activation of Aryl Hydrocarbon Receptor 
260 |b Frontiers Media S.A.,   |c 2021-01-01T00:00:00Z. 
500 |a 1663-9812 
500 |a 10.3389/fphar.2020.619265 
520 |a Tryptamine is a naturally occurring monoamine alkaloid which has been shown to act as an aryl hydrocarbon receptor (AHR) agonist. It is produced in large quantities from the catabolism of the essential amino acid tryptophan by commensal microorganisms within the gastrointestinal (GI) tract of homeothermic organisms. Previous studies have established microbiota derived AHR ligands as potent regulators of neuroinflammation, further defining the role the gut-brain axis plays in the complex etiology in multiple sclerosis (MS) progression. In the current study, we tested the ability of tryptamine to ameliorate symptoms of experimental autoimmune encephalomyelitis (EAE), a murine model of MS. We found that tryptamine administration attenuated clinical signs of paralysis in EAE mice, decreased the number of infiltrating CD4+ T cells in the CNS, Th17 cells, and RORγ T cells while increasing FoxP3+Tregs. To test if tryptamine acts through AHR, myelin oligodendrocyte glycoprotein (MOG)-sensitized T cells from wild-type or Lck-Cre AHRflox/flox mice that lacked AHR expression in T cells, and cultured with tryptamine, were transferred into wild-type mice to induce passive EAE. It was noted that in these experiments, while cells from wild-type mice treated with tryptamine caused marked decrease in paralysis and attenuated neuroinflammation in passive EAE, similar cells from Lck-Cre AHRflox/flox mice treated with tryptamine, induced significant paralysis symptoms and heightened neuroinflammation. Tryptamine treatment also caused alterations in the gut microbiota and promoted butyrate production. Together, the current study demonstrates for the first time that tryptamine administration attenuates EAE by activating AHR and suppressing neuroinflammation. 
546 |a EN 
690 |a neuroinflammation 
690 |a tryptamine 
690 |a experimental autoimmune encephalitis 
690 |a aryl hydrocarbon receptor 
690 |a autoimmunity 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Frontiers in Pharmacology, Vol 11 (2021) 
787 0 |n https://www.frontiersin.org/articles/10.3389/fphar.2020.619265/full 
787 0 |n https://doaj.org/toc/1663-9812 
856 4 1 |u https://doaj.org/article/8d1e3529ef0d439ea862c9f5fb1ad7ad  |z Connect to this object online.